Recruiting
Phase 1

Sirolimus

Sponsor:

University of Missouri-Columbia

Code:

NCT07728175

Conditions

Genetic Predisposition to Disease

Healthy Volunteer

APOE-4 Positive

Eligibility Criteria

Sex: Female

Age: 45 - 65

Healthy Volunteers: Accepted

Interventions

Sirolimus (rapamycin)

Placebo

Study Details

Brief summary:

Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure.

Sirolimus (Rapamycin) is an FDA-approved medication which may improve the blood flow to the brain. The purpose of the clinical trial is to find out whether sirolimus can help improve blood flow and energy use in the brain in women ages 45 to 65 who have the ApoE4 gene, a gene which increases the risk of developing Alzheimer's disease later in life.

There will be two arms in this trail, a sirolimus arm and a placebo arm. A placebo is a pill that looks like the study drug, but it does not have any real medicine in it. Participants will be randomized to one arm or the other, but not to both arms. Three study visits over a 12-week period are required.

Participants will: (i) Complete some questionnaires about how well you think; (ii) Complete genetic testing for the ApoE4 gene; (iii) Have blood work, blood pressure and height and weight collected; (iv) Take either Sirolimus or a placebo daily, by mouth, for approximately 4 weeks; (v) Keep a diary of when the sirolimus or placebo is taken; (vi) Complete 2 Magnetic Resonance Imaging (MRI) exams

Conditions

Genetic Predisposition to Disease

Healthy Volunteer

APOE-4 Positive

Study ID

NCT07728175

Start date

Dec 1, 2026

Status verified date

Sep, 2026

Completion date

Jul 7, 2028

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 45 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Willing and able to provide informed consent
2. Sex assigned at birth: female
3. 45-65 years old
4. Able to perform self-care and activities of daily living with no or minimal assistance
5. Post-menopausal status or use of highly effective contraception. Post-menopausal is defined as either

  • 12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g., age-appropriate, history of vasomotor symptoms)
  • surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks prior to screening. For oophorectomy alone, post-menopausal status must be confirmed by follow-up hormone level assessment
  • Highly effective contraception includes intrauterine devices (IUD), oral contraceptives, or other hormonal contraceptives including injectables, transdermal patches, implants or vaginal rings, or refraining from heterosexual intercourse during the 4 weeks of taking the study drug and for 2 weeks after no longer taking the study drug
6. Body weight of ≥ 40 kg
7. Ability to effectively communicate with the investigator and comply with study requirements

Exclusion Criteria:

1. Diagnosis of mild cognitive impairment (MCI), dementia, or Alzheimer's disease
2. BMI ≥ 35 (based on MRI feasibility)
3. Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c ≥ 6.5%)
4. History of skin ulcers or poor wound healing
5. Current tobacco or illicit drug use or alcohol abuse (defined as ≥ 3 per day or ≥ 7 per week for women) (Per NIAAA guidelines)
6. Use of anti-platelet or anti-coagulant medications other than aspirin
7. Required use of medications that affect cytochrome P450 3A4 (CYP3A4) or alter cerebral blood flow (see Appendix 1 for tables of excluded medications)
8. Immunosuppressant therapy within the last year
9. Chemotherapy or radiation treatment within the last year
10. Current or chronic history of liver or kidney disease or known hepatic or biliary abnormalities
11. Untreated hypertriglyceridemia (fasting triglycerides < 300 mg/dl)
12. Current or chronic significant history of pulmonary disease
13. Chronic heart failure
14. Pregnancy or lactation
15. Recent history (past six months) of myocardial infarction, active coronary artery disease, intestinal disorders, stroke, or transient ischemic attack
16. Poorly controlled blood pressure (systolic BP > 160 or diastolic BP > 100 mmHg)
17. Active inflammatory, COVID-19, autoimmune, infectious, hepatic, gastrointestinal, malignant, and/or severe mental illness
18. History of, or MRI, or CT positive for, any space occupying brain lesion, including mass effect or abnormal intracranial pressure
19. Organ transplant recipients
20. History of Stroke
21. History of ruptured intracranial aneurysm
22. History of malignancy within the past 2 years, with the following exceptions:

  • Localized basal cell or squamous cell carcinoma of the skin
  • Prostate cancer confined to the gland (AJCC stage T2N0M0 or better)
  • Cervical carcinoma in situ
  • Breast cancer localized to the breast
23. History of epilepsy

Study Design

Enrollment

225 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

active comparator: Sirolimus

placebo comparator: Placebo

Interventions

Sirolimus (rapamycin)

Participants in Sirolimus arm will receive Sirolimus.

Placebo

Participants in the Placebo arm will receive Placebo

Primary outcome measure

  • Change in Cerebral Blood Flow as measured by MRI [ Time Frame: Baseline to 4 weeks ]

Central Contacts and Locations

Locations

University of Missouri

Recruiting

Columbia, Missouri, United States, 65212

Contacts

Principal Investigator:

Ai-Ling Lin, PhD

More Information

Sponsor

University of Missouri-Columbia

Last update posted

Oct 5, 2026

Last verified

Sep, 2026

Keywords

  • ApoE4 positive
  • Cerebral Blood Flow
  • Sirolimus
  • Rapamycin
  • Magnetic Resonance Imaging

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-06. This information was provided to ClinicalTrials.gov by University of Missouri-Columbia on 2026-10-05. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.